Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a con

Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy a

Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high

Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) duri

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face

Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent

RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outp

Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equ

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ul

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporti

Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat th

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully i

BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully i

BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maint

Bank of New York Mellon Corp raised its holdings in Praxis Precision Medicines, Inc. (NASDAQ: PRAX)

Fifth Third Bancorp bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the

Praxis Precision Medicines: Priced For Half Of What I Think It's Worth

Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX)

Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route    

Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route    

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully i

FDA sets updated PDUFA date of December 27, 2026BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Pre

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Pr

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises

Praxis Precision Medicines Inc. (NASDAQ:PRAX) said on Monday that the U.S. Food and Drug Administrat

FDA grants Breakthrough Therapy Designation to Praxis' elsunersen after strong seizure reduction

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system

The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAV

RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX)

Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conf

Praxis Precision Medicines, Inc. is valued as a pure-play on ulixacaltamide's commercial launch in e

BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully i

Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform

Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a

Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy an

Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform

Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H

Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and

HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) wi

Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose

BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers

POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary succes

HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) w

BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maint

Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a